Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,777 GBX | +0.21% | +2.98% | +22.74% |
08/05 | Gsk plc Announces Board Committee Changes | CI |
08/05 | GSK : Receives a Buy rating from Bernstein | ZD |
Sales 2024 * | 31.61B 39.43B 3,293B | Sales 2025 * | 33.56B 41.86B 3,496B | Capitalization | 72.32B 90.22B 7,535B |
---|---|---|---|---|---|
Net income 2024 * | 5.59B 6.97B 582B | Net income 2025 * | 6.47B 8.07B 674B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 12.3B 15.35B 1,282B | Net Debt 2025 * | 9.1B 11.35B 948B | EV / Sales 2025 * | 2.43 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
11.2
x | Employees | 70,212 |
Yield 2024 * |
3.44% | Yield 2025 * |
3.57% | Free-Float | 94.38% |
Latest transcript on GSK plc
1 day | +0.38% | ||
1 week | +2.96% | ||
Current month | +6.38% | ||
1 month | +10.13% | ||
3 months | +7.21% | ||
6 months | +25.74% | ||
Current year | +22.72% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01/10/01 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 01/23/01 |
James Ford
CMP | Compliance Officer | - | 01/95/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 01/23/01 |
Jonathan Symonds
CHM | Chairman | 66 | 01/19/01 |
Hal Barron
BRD | Director/Board Member | 62 | 01/18/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 0 M€ | +5.54% | - | |
2.51% | 0 M€ | +7.65% | - |
Date | Price | Change | Volume |
---|---|---|---|
09/24/09 | 1,780 | +0.38% | 593 200 |
08/24/08 | 1,774 | +0.71% | 6,684,171 |
07/24/07 | 1,761 | +1.59% | 14,302,770 |
03/24/03 | 1,734 | +0.29% | 4,237,170 |
02/24/02 | 1,728 | +1.38% | 6,275,228 |
Delayed Quote London S.E., May 09, 2024 at 02:27 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.72% | 90.35B | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.85% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- GSK Stock